These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31799889)

  • 21. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Japan after introduction of the routine immunization program.
    Miyazaki H; Shibuya R; Midorikawa N; Chang B; Ohnishi M; Matsumoto T
    J Infect Chemother; 2017 Apr; 23(4):234-240. PubMed ID: 28161295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution and annual changes in the proportion of Streptococcus pneumoniae serotypes in Japanese adults with pneumococcal pneumonia from 2011 to 2017.
    Noguchi S; Yatera K; Akata K; Chang B; Ikegami H; Hata R; Yamasaki K; Kawanami T; Mukae H
    J Infect Chemother; 2019 Nov; 25(11):925-929. PubMed ID: 31350184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Coverage With Influenza, Pneumococcal, and Herpes Zoster Vaccines Among Patients With Rheumatic Diseases in a Nationwide Healthcare Plan.
    Furer V; Weil C; Chodik G; Slav SA; Blonder SN; Fisher-Shoval Y; Barak M; Elkayam O
    J Rheumatol; 2024 May; 51(5):505-516. PubMed ID: 38302167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumococcal polysaccharide vaccination among adults aged 65 years and older, U.S., 1989-2008.
    Lu PJ; Nuorti JP
    Am J Prev Med; 2010 Oct; 39(4):287-95. PubMed ID: 20837278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
    Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
    Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013.
    Ubukata K; Chiba N; Hanada S; Morozumi M; Wajima T; Shouji M; Iwata S;
    Emerg Infect Dis; 2015 Nov; 21(11):1956-65. PubMed ID: 26485679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Social capital and pneumococcal vaccination (PPSV23) in community-dwelling older Japanese: a JAGES multilevel cross-sectional study.
    Iwai-Saito K; Shobugawa Y; Kondo K
    BMJ Open; 2021 Jun; 11(6):e043723. PubMed ID: 34140341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence.
    Niederman MS; Folaranmi T; Buchwald UK; Musey L; Cripps AW; Johnson KD
    Expert Rev Vaccines; 2021 Mar; 20(3):243-256. PubMed ID: 33478306
    [No Abstract]   [Full Text] [Related]  

  • 30. Pneumococcal vaccination, but not influenza vaccination, is negatively associated with incident dementia among Japanese older adults: The JAGES 2013-2022 prospective cohort study.
    Iwai-Saito K; Sato K; Fujii M; Kondo K
    Brain Behav Immun; 2024 Aug; 120():452-463. PubMed ID: 38925416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year.
    Pierre É; Pladys A; Bayat-Makoei S; Tattevin P; Vigneau C
    Vaccine; 2023 Jun; 41(24):3655-3662. PubMed ID: 37179164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
    Zhao D; Gai Tobe R; Cui M; He J; Wu B
    Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.
    Frenck RW; Yeh S
    Expert Opin Biol Ther; 2012 Jan; 12(1):63-77. PubMed ID: 22074323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
    Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease.
    Kopp A; Mangin O; Gantzer L; Lekens B; Simoneau G; Ravelomanantsoa M; Evans J; Bergmann JF; Sellier P
    Hum Vaccin Immunother; 2021 Jan; 17(1):162-169. PubMed ID: 32429734
    [No Abstract]   [Full Text] [Related]  

  • 37. A virtual clinic improves pneumococcal vaccination coverage among patients living with HIV at a Veterans Affairs Medical Center.
    Burns CM; Banks RE; Wilson BM; Carter RR; Jump RLP; Perez F
    AIDS Care; 2018 Feb; 30(2):146-149. PubMed ID: 29052434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.
    Ahmed SS; Pondo T; Xing W; McGee L; Farley M; Schaffner W; Thomas A; Reingold A; Harrison LH; Lynfield R; Rowlands J; Bennett N; Petit S; Barnes M; Smelser C; Beall B; Whitney CG; Pilishvili T
    Clin Infect Dis; 2020 Jun; 70(12):2484-2492. PubMed ID: 31402387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.